This confirms what we already knew... As reported today at the European Society of Cardiology in Amsterdam: "Women with AF receive less anticoagulation treatment than men despite the fact that they are at greater risk of stroke. The new CHA2DS2-VASc score should be used more stringently, especially in women, to optimise their treatment. Treatment of …
Read More
StopAfib.org interviews Dr. Daniel Singer, of Harvard Medical School. Find more information on this topic, Dr. Singer, and a transcript of the interview, at: http://stopafib.org/newsitem.cfm/NEWSID/394 In this video interview, Dr. Singer discussed topics covered in the stroke prevention in atrial fibrillation symposium he moderated at the Boston AF Symposium 2011. The topics discussed included the …
Read More
In this important video interview at Venice Arrhythmias, Professor Gregory Lip discusses the importance of the CHA2DS2-VASc scoring tool for predicting atrial fibrillation stroke risk and why aspirin is not appropriate for preventing strokes. Watch the video at: Professor Gregory Lip Discusses CHA2DS2-VASc Tool for Predicting Stroke Risk in Atrial Fibrillation — Video
Read More
For Stroke Awareness Month in May, StopAfib.org, an atrial fibrillation patient advocacy organization for those living with atrial fibrillation, recounted the activities focused on raising awareness of atrial fibrillation to avert a stroke crisis. These included continued participation in the Facing AFib campaign, which launched a new pledge by spokesperson Susan Lucci and her husband …
Read More
StopAfib.org will participate in the National Stroke Association's first annual Virtual Health Fair on Wednesday, January 19, 2011. Learn more now about this free online event and how to register. The Virtual Health Fair is open to anyone interested in stroke prevention and recovery. This event will be like a local health fair – except …
Read More
StopAfib.org has published the 2010 Most Popular Atrial Fibrillation News Stories and Videos List. Stroke prevention topped the list and included stories about warfarin (Coumadin) and alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto). Other popular topics included the new European atrial fibrillation guidelines, new antiarrhythmic medications, updates on catheter ablation and afib surgery, and …
Read More
In late breaking clinical trials presented today at the American Heart Association Scientific Sessions, results of the ROCKET AF trial indicated that in an atrial fibrillation patient population that was at a very high risk of stroke, rivaroxaban (Xarelto) was as good as warfarin at preventing strokes. Learn more at: Rivaroxaban comparable to warfarin in …
Read More
Not all atrial fibrillation patients are candidates for an ablation, either catheter ablation or surgical ablation, such as the maze or mini maze procedures. Thus their stroke risk remains high. We recently wrote about the FDA’s approval of the AtriClip device, which is implanted during open heart surgery and reduces stroke risk by occluding (closing …
Read More
AF patients are generally at a higher risk for stroke and thus may have to take anticoagulant medications, such as Coumadin or warfarin, to manage their afib-related stroke risk. With the FDA's recent approval of AtriCure's AtriClip device that is implanted during open heart surgery, afib patients and their doctors may now have another way …
Read More
In this video interview, Dr. Nassir Marrouche, Executive Director of the Comprehensive Arrhythmia Research and Management (CARMA) Center at the University of Utah Health System, discusses the findings he recently presented at the Heart Rhythm Society annual meeting in Denver. He discussed the intriguing way they are using MRI (magnetic resonance imaging), to personalize atrial …
Read More